
    
      This study is being conducted to satisfy post-marketing commitments to monitor
      anti-idursulfase antibody development in Hunter syndrome patients after long-term idursulfase
      enzyme replacement therapy. The study will be conducted as a sub-study within the Hunter
      Outcome Survey (HOS). Hunter syndrome patients in the HOS who have previously received
      idursulfase as well as treatment-naive patients who will begin idursulfase treatment within
      30 days of study enrollment will be included.
    
  